malononitrilamide-715
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2002 (NCT00451932)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-cyano-3-hydroxy-n-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide
- 2-cyano-3-hydroxy-n-(4--(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid
- fk778
- fk778
- fk778
- fk 778
- fk-778
- hmr 1715
- hmr-1715
- malononitrilamide 715
- malononitrilamide-715
- mna 715
- mna-715
- mna-x 920715
- x 920715
- x-920715
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00104338 | Phase 2 | Jan 1, 2005 | Astellas |
| NCT00282230 | Phase 2 | Nov 1, 2003 | Astellas |
| NCT00189735 | Phase 2 | Sep 1, 2003 | Astellas |
| NCT00451932 | Phase 2 | Oct 1, 2002 | Astellas |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 4 | 4 | 1 | 2002 |
1 organizations
Page 1 / 1